No­vo Nordisk drops two pro­grams as it plots We­govy come­back

Two No­vo Nordisk pro­grams in obe­si­ty and car­dio­vas­cu­lar dis­ease are on the chop­ping block, the com­pa­ny buried in its Q3 re­port, as CEO Lars Fruer­gaard Jør­gensen plots a come­back in obe­si­ty.

The chief ex­ec­u­tive is shut­ting down a Phase I obe­si­ty pro­gram dubbed LA-GDF15 and a PC­SK9 in­hibitor that just com­plet­ed a Phase II tri­al in pa­tients with or at risk of de­vel­op­ing ath­er­o­scle­rot­ic car­dio­vas­cu­lar dis­ease (AS­CVD) due to “port­fo­lio con­sid­er­a­tions,” he said in the Q3 re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER